CARLSBAD, Calif.--(BUSINESS WIRE)--Vektor Medical, Inc. announced that a single-center study conducted at the University of California San Diego reports that use of vMap™ (computational 12-lead ECG analysis) is feasible in patients following infection from COVID-19. The study, presented as part of THRS 2021 Cutting-Edge Care for Heart Rhythm on April 17-18, evaluated five patients 1.8±1.1 months after COVID-19 diagnosis.
COVID-19 is associated with myocardial inflammation which may cause or exacerbate arrhythmias. Seven clinical arrhythmias were evaluated in the five patients who had experienced COVID-19; including atrial flutter, atrial fibrillation, and ventricular tachycardia. Notably, vMap analysis provided insights beyond those available from 12-lead ECG in this population.
“Although additional work is required to better understand the relationship between myocardial inflammation and arrhythmias related to COVID-19, we are proud that vMap™ may be able to support clinicians in providing treatment for people inflicted by the COVID-19 disease.” Rob Krummen, COO and General Counsel of Vektor Medical.
About Vektor Medical, Inc.: Vektor Medical has developed a patented, next generation technology designed for functionally mapping cardiac arrhythmias. Vektor Medical was founded in 2017 by a team of engineers, scientists, doctors and entrepreneurs with the shared belief that harnessing the power of computational modeling could vastly improve cardiac arrhythmia care. Vektor Medical is based in Carlsbad, CA. To learn more, visit https://www.vektormedical.com.
About vMap™: vMap™ is a proprietary, non-invasive arrhythmia mapping technology that analyzes the information contained in a patient’s standard ECG. The vMap™ technology has been designed to provide physicians with actionable information on arrhythmias in all four chambers of the heart using a rapid, non-invasive, and workflow-optimized process. These insights are designed to assist the evaluation, investigation, and treatment of the arrhythmia source. Vektor Medical is in the process of applying for FDA clearance for vMap™, which is not currently available for distribution.
